BeOne Medicines (NASDAQ:ONC) Insider Lai Wang Sells 756 Shares of Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) insider Lai Wang sold 756 shares of the business’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $261.00, for a total transaction of $197,316.00. Following the transaction, the insider owned 1,710,085 shares in the company, valued at $446,332,185. This trade represents a 0.04% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Lai Wang also recently made the following trade(s):

• On Monday, June 8th, Lai Wang sold 1,367 shares of BeOne Medicines stock. The shares were sold at an average price of $269.38, for a total transaction of $368,242.46.

BeOne Medicines Stock Up 1.4%

Shares of ONC opened at $268.20 on Tuesday. The firm has a market capitalization of $29.43 billion, a P/E ratio of 60.00 and a beta of 0.49. BeOne Medicines Ltd. – Sponsored ADR has a 12-month low of $239.25 and a 12-month high of $385.22. The company has a current ratio of 3.64, a quick ratio of 3.27 and a debt-to-equity ratio of 0.20. The firm has a fifty day moving average price of $298.56 and a 200-day moving average price of $314.03.

BeOne Medicines (NASDAQ:ONC) last issued its earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. The firm had revenue of $1.51 billion during the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. Equities research analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on ONC shares. Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a research note on Monday, April 20th. Wolfe Research started coverage on shares of BeOne Medicines in a research note on Friday, March 27th. They set an “outperform” rating and a $340.00 target price for the company. Zacks Research raised shares of BeOne Medicines from a “hold” rating to a “strong-buy” rating in a research note on Thursday, June 4th. Wall Street Zen raised shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Finally, Wells Fargo & Company initiated coverage on shares of BeOne Medicines in a research note on Monday, May 4th. They set an “overweight” rating and a $400.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, BeOne Medicines has a consensus rating of “Moderate Buy” and an average target price of $390.00.

Institutional Trading of BeOne Medicines

Several hedge funds have recently modified their holdings of ONC. EFG International AG purchased a new stake in shares of BeOne Medicines during the fourth quarter valued at about $25,000. Leonteq Securities AG purchased a new stake in shares of BeOne Medicines during the fourth quarter valued at about $35,000. Daiwa Securities Group Inc. purchased a new stake in shares of BeOne Medicines during the second quarter valued at about $35,000. CWM LLC lifted its position in shares of BeOne Medicines by 32.8% during the fourth quarter. CWM LLC now owns 158 shares of the company’s stock valued at $48,000 after buying an additional 39 shares during the last quarter. Finally, Group One Trading LLC purchased a new stake in shares of BeOne Medicines during the fourth quarter valued at about $61,000. 48.55% of the stock is owned by hedge funds and other institutional investors.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.